Squitieri Ferdinando, Orobello Sara, Cannella Milena, Martino Tiziana, Romanelli Pantaleo, Giovacchini Giampiero, Frati Luigi, Mansi Luigi, Ciarmiello Andrea
Neurogenetics Unit & Centre for Rare Disease, IRCCS Neuromed, Località Camerelle, 86077, Pozzilli, Italy.
Eur J Nucl Med Mol Imaging. 2009 Jul;36(7):1113-20. doi: 10.1007/s00259-009-1103-3. Epub 2009 Mar 11.
Huntington disease (HD) mutation increases gain-of-toxic functions contributing to glutamate-mediated excitotoxicity. Riluzole interferes with glutamatergic neurotransmission, thereby reducing excitotoxicity, enhancing neurite formation in damaged motoneurons and increasing serum concentrations of BDNF, a brain cortex neurotrophin protecting striatal neurons from degeneration.
We investigated metabolic and volumetric differences in distinct brain areas between 11 riluzole-treated and 12 placebo-treated patients by MRI and (18)F-fluoro-2-deoxy-D-glucose (FDG) PET scanning, according to fully automated protocols. We also investigated the influence of riluzole on peripheral growth factor blood levels.
Placebo-treated patients showed significantly greater proportional volume loss of grey matter and decrease in metabolic FDG uptake than patients treated with riluzole in all cortical areas (p<0.05). The decreased rate of metabolic FDG uptake correlated with worsening clinical scores in placebo-treated patients, compared to those who were treated with riluzole. The progressive decrease in metabolic FDG uptake observed in the frontal, parietal and occipital cortex correlated linearly with the severity of motor scores calculated by Unified Huntington Disease Rating Scale (UHDRS-I) in placebo-treated patients. Similarly, the rate of metabolic changes in the frontal and temporal areas of the brain cortex correlated linearly with worsening behavioural scores calculated by UHDRS-III in the placebo-treated patients. Finally, BDNF and transforming growth factor beta-1 serum levels were significantly higher in patients treated with riluzole.
The linear correlation between decreased metabolic FDG uptake and worsening clinical scores in the placebo-treated patients suggests that FDG-PET may be a valuable procedure to assess brain markers of HD.
亨廷顿舞蹈病(HD)突变会增加毒性功能获得,导致谷氨酸介导的兴奋性毒性。利鲁唑可干扰谷氨酸能神经传递,从而降低兴奋性毒性,增强受损运动神经元的神经突形成,并提高脑源性神经营养因子(BDNF)的血清浓度,BDNF是一种保护纹状体神经元免于退化的大脑皮质神经营养因子。
我们根据全自动方案,通过MRI和(18)F-氟-2-脱氧-D-葡萄糖(FDG)PET扫描,研究了11例接受利鲁唑治疗的患者和12例接受安慰剂治疗的患者在不同脑区的代谢和体积差异。我们还研究了利鲁唑对外周生长因子血液水平的影响。
在所有皮质区域,接受安慰剂治疗的患者灰质体积损失比例和代谢性FDG摄取降低程度均显著大于接受利鲁唑治疗的患者(p<0.05)。与接受利鲁唑治疗的患者相比,接受安慰剂治疗的患者代谢性FDG摄取降低率与临床评分恶化相关。在接受安慰剂治疗的患者中,额叶、顶叶和枕叶皮质观察到的代谢性FDG摄取逐渐降低与统一亨廷顿舞蹈病评定量表(UHDRS-I)计算的运动评分严重程度呈线性相关。同样,在接受安慰剂治疗的患者中,大脑皮质额叶和颞叶区域的代谢变化率与UHDRS-III计算的行为评分恶化呈线性相关。最后,接受利鲁唑治疗的患者血清BDNF和转化生长因子β-1水平显著更高。
接受安慰剂治疗的患者代谢性FDG摄取降低与临床评分恶化之间的线性相关性表明,FDG-PET可能是评估HD脑标志物的一种有价值的方法。